EPO rejects Soliris patent, schedules oral hearing

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said the European Patent Office has rejected a patent that would extend exclusivity through 2027 for

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE